UltiMapper multiplex immuno-histochemistry assays enable the precise identification of cellular phenotypes that can be associated to drug efficacy and further used to develop a companion diagnostic assay.
“UltiMapper assays are very modular by design, allowing for various levels of multiplexing and throughput, and supporting same day staining-to-data workflows,” stated Dr. Thomas Henkel, CEO of Targos. “The adoption of highly standardized multiplex tissue biomarker assays is a strategic fit with our mission to continuously improve the success of clinical trials and deliver exceptional value to our biopharma partners.”
Ultivue technologies and UltiMapper assays are widely used in tumor immune-profiling research strategies by the biomedical community to demonstrate the clinical utility of panels of markers. “Through our collaboration with Targos, the same panels can seamlessly be used in their existing setup to create a very effective continuum of translational and clinical research,” said Philippe Mourere, SVP Commercial Operations at Ultivue. “Targos also ...
